Both autologous bone marrow mononuclear cell and peripheral blood progenitor cell therapies similarly improve ischaemia in patients with diabetic foot in comparison with control treatment

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 5, 2013, Pages 369-376

  Dubsky, M ^a,d   Jirkovska, A ^a   Bem, R ^a   Fejfarova, V ^a   Pagacova, L ^b   Sixta, B ^c   Varga, M ^c   Langkramer, S ^d   Sykova, E ^e   Jude, E B ^f  

^a Diabetes Centre   (Czech Republic)

^b Autotransfusion Unit   (Czech Republic)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^f TAMESIDE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Critical limb ischaemia; Diabetic foot; Stem cell therapy

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CELL SUSPENSION; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DIABETIC FOOT; DIABETIC PATIENT; ENDARTERECTOMY; FEMALE; HEART FAILURE; HUMAN; LIMB AMPUTATION; LIMB ISCHEMIA; LYMPHOCYTE; MALE; MICROANGIOPATHY; MONOCYTE; MONONUCLEAR CELL; NEUTROPHIL; OPHTHALMOSCOPY; OUTCOME ASSESSMENT; OXYGEN TENSION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVASCULARIZATION; STEM CELL TRANSPLANTATION; THROMBOCYTE;

EID: 84880033478     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2399     Document Type: Article

References (43)

1. International Working Group on the Diabetic Foot. International consensus on the diabetic foot & practical guidelines on the management and prevention of the diabetic foot. 2011.
2. Prompers L, Schaper N, Apelqvist J, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia 2008; 51(5): 747-755.
3. Amann B, Leudemann C, Ratei R, Schmidt-Lucke JA. Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease. Cell Transplant 2009; 18(3): 371-380.
4. Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005; 28(9): 2155-2160.
5. Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes - a review. Diabet Med 2010; 27(1): 4-14.
6. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360(9331): 427-4235.
7. Lawall H, Bramlage P, Amann B. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal. Thromb Haemost 2010; 103(4): 696-709.
8. Powell RJ, Marston WA, Berceli SA, et al. Cellular therapy with ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol Ther 2012; 20(6): 1280-1286.
9. Yeh ET, Zhang S, Wu HD, et al. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation 2003; 108(17): 2070-2073.
10. Aranguren XL, Verfaillie CM, Luttun A. Emerging hurdles in stem cell therapy for peripheral vascular disease. J Mol Med 2009; 87(1): 3-16.
11. Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005; 45(9): 1449-1457.
12. Fadini GP, Boscaro E, de Kreutzenberg GP, et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care 2010; 33(5): 1097-1102.
13. Fadini GP, Albiero M, Boscaro E, Agostini C, Avogaro A. Endothelial progenitor cells as resident accessory cells for post-ischemic angiogenesis. Atherosclerosis 2009; 204(1): 20-22.
14. Di Vita G, Patti R, D'Agostino P, et al. Serum VEGF and b-FGF profiles after tension-free or conventional hernioplasty. Langenbeck's Arch Surg 2005; 390(6): 528-533.
15. Huang PP, Yang XF, Li SZ, Wen JC, Zhang Y, Han ZC. Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost 2007; 98(6): 1335-1342.
16. Attanasio S, Snell J. Therapeutic angiogenesis in the management of critical limb ischemia: current concepts and review. Cardiol Rev 2009; 17(3): 115-120.
17. Matoba S, Tatsumi T, Murohara T, et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J 2008; 156(5): 1010-1018.
18. Miyamoto K, Nishigami K, Nagaya N, et al. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation 2006; 114(24): 2679-2684.
19. Ferrara N. Vascular endothelial growth factor. The trigger for neovascularization in the eye. Lab Invest 1995; 72(6): 615-618.
20. Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev 2004; 20(Suppl 1): S90-S95.
21. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26(3): 517-538.
22. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33(Suppl 1): S1-75.
23. Graziani L, Silvestro A, Bertone V, et al. Vascular involvement in diabetic subjects with ischemic foot ulcer: a new morphologic categorization of disease severity. Eur J Vasc Endovasc Surg 2007; 33(4): 453-460.
24. Lavery LA, Armstrong DG, Harkless LB. Classification of diabetic foot wounds. J Foot Ankle Surge 1996; 35(6): 528-531.
25. International Working Group on the Diabetic Foot. International Consensus on the Diabetic Foot. 2011.
26. Sykova E, Homola A, Mazanec R, et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant 2006; 15(8-9): 675-687.
27. Al Mheid I, Quyyumi AA. Cell therapy in peripheral arterial disease. Angiology 2008; 59(6): 705-716.
28. De Vriese AS, Billiet J, Van Droogenbroeck J, Ghekiere J, De Letter A. Autologous transplantation of bone marrow mononuclear cells for limb ischemia in a Caucasian population with atherosclerosis obliterans. J Intern Med 2008; 263(4): 395-403.
29. Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 2010; 209(1): 10-17.
30. Kawamura A, Horie T, Tsuda I, et al. Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs 2006; 9(4): 226-233.
31. Klepanec A, Mistrik M, Altaner C, et al. No difference in intraarterial and intramuscular delivery of autologous bone-marrow cells in patients with advanced critical limb ischemia. Cell Transplant 2012; 21(9): 1909-1918.
32. Walter DH, Krankenberg H, Balzer JO, et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv 2011; 4(1): 26-37.
33. Onodera R, Teramukai S, Tanaka S, et al. Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis. Bone Marrow Transplant 2011; 46(2): 278-284.
34. Apelqvist JA, Lepantalo MJ. The ulcerated leg: when to revascularize. Diabetes Metab Res Rev 28(Suppl 1): 30-35.
35. Powell RJ, Comerota AJ, Berceli SA, et al. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. J Vasc Surg 2011; 54(4): 1032-1041.
36. Canizo MC, Lozano F, González-Porras JR, et al. Peripheral endothelial progenitor cells (CD133+) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up. Cytotherapy 2007; 9(1): 99-102.
37. Kudo FA, Nishibe T, Nishibe M, Yasuda K. Autologous transplantation of peripheral blood endothelial progenitor cells (CD34+) for therapeutic angiogenesis in patients with critical limb ischemia. Int Angiol 2003; 22(4): 344-348.
38. Prochazka V, Gumulec J, Jalůvka F, et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant 2010; 19(11): 1413-1424.
39. Lu D, Chen B, Liang Z, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract 2011; 92(1): 26-36.
40. Kajiguchi M, Kondo T, Izawa H, et al. Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J 2007; 71(2): 196-201.
41. Siddiq S, Pamphilon D, Brunskill S, Doree C, Hyde C, Stanworth S. Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donors. Cochrane Database Syst Rev 2009; (1): CD006406.
42. Hinchliffe RJ, Andros G, Apelqvist J, et al. A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. Diabetes Metab Res Rev 2012; 28(Suppl 1): 179-217.
43. Young MJ, McCardle JE, Randall LE, Barclay JI. Improved survival of diabetic foot ulcer patients 1995-2008: possible impact of aggressive cardiovascular risk management. Diabetes Care 2008; 31(11): 2143-2147.